Homepage > Company > Media > Pharma News > 2017 > FDA approves Perrigo’s Exalgo extended-release generic

FDA approves Perrigo’s Exalgo extended-release generic

SILVER SPRING, Md. — Perrigo is adding to its portfolio of opioid generics. The Food and Drug Administration has approved the company’s generic of Exalgo (hydromorphone HCL, 32 mg) extended-release tablets.

Картинки по запросу hydromorphone HCL

The drug is an opioid indicated to manage moderate to severe pain in patients requiring continuous around-the-clock pain opioid analgesia for an extended period of time. Perrigo said it planned to make the generic available by the end of September.

The drug had brand and generic sales of $35 million for the 12 months ended July 2017, the company said.

September 21, 2017

http://www.drugstorenews.com/

Read also

Ventus and Genentech

Ventus and Genentech partner for small-molecule medicine discovery

Aspire Pharma’s

Acquisition strengthens Aspire Pharma’s strategic portfolio

Alkermes to acquire Avadel for $2.1bn

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn.

NanoViricides

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies